We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Omega-3 Supplementation and Depression Clinical Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01614249
Recruitment Status : Completed
First Posted : June 7, 2012
Results First Posted : March 8, 2016
Last Update Posted : March 8, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:

Fish oil omega-3 supplements provide essential nutrients for brain health and functioning. These nutrients have been proven to be effective in reducing depressive symptoms. They have also been found to be effective and well tolerated in reducing the bad fat accumulation among patients infected with human immunodeficiency virus (HIV)and are using highly active antiretroviral treatment. The role of this nutritional supplement in combating depression among pregnant women who are living with HIV infection has however not been established. Yet, currently, more than 2 million pregnant women are estimated to be living with HIV infection globally. In Kenya, about 9.0% of pregnant women are HIV-seropositive.

In this study, it is hypothesized that there is no difference in the levels of depressive symptoms among HIV infected pregnant women who are taking omega-3 fish oil supplements and those taking a placebo.

The study will therefore seek to ascertain that taking omega-3 fish oil nutritional supplement has a significant positive effect on depressive symptoms among HIV infected pregnant women, compared to a placebo.

Condition or disease Intervention/treatment Phase
Depressive Symptoms Dietary Supplement: Soybean oil soft gels Dietary Supplement: Fish oil omega-3 EPA-rich soft gels Phase 2 Phase 3

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Role of Omega-3 Fish Oil Fatty Acids on Depression Among HIV-seropositive Pregnant Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial
Study Start Date : June 2012
Primary Completion Date : July 2013
Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Soybean oil soft gels
Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
Dietary Supplement: Soybean oil soft gels
Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
Other Name: OmegaVia Soybean oil soft gels
Experimental: Fish oil omega-3 EPA-rich soft gels
Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
Dietary Supplement: Fish oil omega-3 EPA-rich soft gels
A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
Other Name: OmegaVia fish oil omega-3 EPA-rich soft gels

Outcome Measures

Primary Outcome Measures :
  1. Change in BDI-II Depressive Symptom Scores [ Time Frame: 8 weeks ]
    Depressive symptoms were assessed by Beck Depression Inventory Second Edition (BDI-II) Scoring scale at Baseline and end of study during the 8- week study period. The BDI-II Scale is a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe).Scores for each symptom are added up to obtain the total scores for all 21 items, which are interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression. The change in BDI-II scores were computed from post-intervention scores at week 8 and baseline BDI-II scores at week 0.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years to 49 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All pregnant HIV seropositive women with known CD4 cell count less than 500
  • Pregnant women who are in their 2nd trimester of pregnancy (Week 13-27).
  • Normal nutritional status pregnancy with mid-upper arm circumference (MUAC of 22 cm - 33 cm)at entry into the study;
  • Beck Depression Inventory Second Edition (BDI-II) Scale scores at entry into the study of 14 or more;
  • Pregnant HIV positive women who will give consent to participate in the study

Exclusion Criteria:

  • Underweight with MUAC less than 22 cm and overweight with MUAC more than 33 cm at entry into the study;
  • Pregnant women taking antidepressant medications;
  • Those on anti-clotting medication (those with liver disease, varicose veins, peptic ulcers); or Vitamin K supplement. Omega-3 supplements may increase their effects;
  • Those on diabetic medication since Omega-3 may increase their blood sugar.
  • Incomplete depression screening form (more than 5 items unanswered)
  • Those whose BDI-II screening scores are less than 14;
  • Those women currently taking omega-3 nutritional supplement
  • Pregnant HIV-seropositive women without consent to participate in the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01614249

Nairobi City Council Health Facilities
Nairobi, Kenya, 020
Sponsors and Collaborators
University of Nairobi
Consortium for Advanced Research Training in Africa (CARTA)
Innovix Pharma Inc.
Principal Investigator: Rose O. Opiyo, MSc University of Nairobi
More Information

Jones, P. and A. Papamandjaris, eds. Lipid: Cellular Metabolism in Present Knowledge in Nutrition. 8th ed. Present Knowledge in Nutrition, ed. B. Bowman and R. Russell2001, ILSI Press: Washington, DC. 104-114.
Stoll, A., The Omega-3 connection.2001, New York.: Simon & Schuster.
WHO/UNAIDS/UNICEF, Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report, April 2007., 2007.
Melina, V. and B. Davis, The New Becoming Vegetarian. The essential guide to a healthy vegetarian diet. 2003, Tennessee: Healthy Living Publications.
NASCOP, Kenya AIDS Indicator Survey, (KAIS) 2007, 2009, NASCOP: Nairobi. p. 11.
KNBS, Kenya 2009 Population and Housing Census, M.o.P.a.N. Development, Editor 2010, Government Printers: Nairobi.
NASCOP/MOH/CDC, Sentinel Surveillance of HIV & STDs in Kenya Report 2006, 2006, NASCOP: Nairobi.

Responsible Party: Rose Okoyo Opiyo, Principal Investigator (PI), University of Nairobi
ClinicalTrials.gov Identifier: NCT01614249     History of Changes
Other Study ID Numbers: ODR-2011/2012
ECCT/12/03/01 ( Registry Identifier: Pharmacy and Poisons Board, Kenya )
First Posted: June 7, 2012    Key Record Dates
Results First Posted: March 8, 2016
Last Update Posted: March 8, 2016
Last Verified: February 2016

Keywords provided by Rose Okoyo Opiyo, University of Nairobi:
HIV infected
Pregnant women

Additional relevant MeSH terms:
Behavioral Symptoms